Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy

Patent No. EP3126390 (titled "Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy") was filed by Cellectis on Apr 2, 2015. The application was issued on Jan 7, 2026.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBJul 14, 2020WICHMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3126390

CELLECTIS
Application Number
EP15713513A
Filing Date
Apr 2, 2015
Status
Patent Maintained As Amended
Dec 5, 2025
Publication Date
Jan 7, 2026